losartan has been researched along with Hypercholesterolemia in 34 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hypercholesterolemia: A condition with abnormally high levels of CHOLESTEROL in the blood. It is defined as a cholesterol value exceeding the 95th percentile for the population.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia." | 9.24 | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. ( Cha, DH; Choi, JH; Choi, JY; Choi, KJ; Choi, SW; Hong, TJ; Jung, HO; Kim, KH; Kim, SM; Kim, SY; Kim, WS; Lee, HY; Lee, KJ; Oh, JH; Park, DG; Park, SW; Park, TH; Rha, SW; Rhee, MY; Ryu, DR; Shim, J; Song, PS; Yoo, BS, 2017) |
| "Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure." | 9.14 | Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. ( Filiopoulos, V; Georgoulias, C; Kosmadakis, G; Michail, S; Tentolouris, N, 2010) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 9.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| "The objective of this study was to evaluate the efficacy and tolerability of a triple combination of amlodipine/losartan/rosuvastatin in patients with hypertension and hypercholesterolemia." | 5.24 | A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia. ( Cha, DH; Choi, JH; Choi, JY; Choi, KJ; Choi, SW; Hong, TJ; Jung, HO; Kim, KH; Kim, SM; Kim, SY; Kim, WS; Lee, HY; Lee, KJ; Oh, JH; Park, DG; Park, SW; Park, TH; Rha, SW; Rhee, MY; Ryu, DR; Shim, J; Song, PS; Yoo, BS, 2017) |
| "Treatment with lisinopril and losartan in nephrotic patients with idiopathic membranous nephropathy results in similar (and significant) effects on renal function, hypoalbuminaemia, proteinuria and blood pressure." | 5.14 | Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome. ( Filiopoulos, V; Georgoulias, C; Kosmadakis, G; Michail, S; Tentolouris, N, 2010) |
| "The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study showed that treatment with the angiotensin II type-1 receptor antagonist losartan reduces overall stroke risk compared with conventional therapy with the beta-blocker atenolol." | 5.11 | Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. ( Beevers, G; Dahlöf, B; de Faire, U; Devereux, RB; Edelman, JM; Fyhrquist, F; Harris, KE; Ibsen, H; Julius, S; Kizer, JR; Kjeldsen, SE; Kristianson, K; Lederballe-Pedersen, O; Lindholm, LH; Nieminen, MS; Omvik, P; Oparil, S; Snapinn, SM; Wachtell, K; Wedel, H, 2005) |
| " The LIFE study concluded that losartan is superior compared to atenolol in terms of prevention of cardiovascular morbidity and mortality, the benefit being for CVA without changing the incidence of myocardial infarction." | 4.82 | [The best of clinical pharmacology in 2002]. ( Ambrosi, P; Andréjak, M; Gayet, JL, 2003) |
| " This study was designed to determine the effect of hypercholesterolemia on LOX-1 expression in aorta and its modulation by the AT(1) receptor blocker losartan." | 3.70 | Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. ( Chen, H; Inoue, K; Li, D; Mehta, JL; Sawamura, T, 2000) |
| " Besides, its cholesterol-lowering effect, the ability of simvastatin to ameliorate endothelial dysfunction through increasing NO bioavailability and through suppression of oxidative stress and vascular inflammation may play an important role in these effects." | 2.79 | Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein. ( Abdel-Zaher, AO; Abudahab, LH; Elbakry, MH; Elkoussi, AE; Elsayed, EA, 2014) |
| "Simvastatin combined with losartan improves endothelial function and reduces inflammatory markers to a greater extent than monotherapy with either drug in hypercholesterolemic, hypertensive patients." | 2.71 | Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. ( Ahn, JY; Ahn, TH; Choi, IS; Chung, WJ; Han, SH; Kang, MH; Koh, KK; Quon, MJ; Seo, YH; Shin, EK, 2004) |
| "Diagnosis of gout is established when typical monosodium urate crystals can be identified." | 2.44 | [Involvement of the foot in metabolic diseases]. ( Gerster, JC, 2007) |
| "Hypertension was induced by L-N(G)-nitroarginine methyl ester (L-NAME) and hypercholesterolemia was induced by feeding rats with a diet containing 1% cholesterol." | 1.46 | Protective effect of the standardized extract of ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms. ( Abd-Eldayem, AM; Abdel-Zaher, AO; El-Refaiy, AEM; Farghaly, HSM, 2017) |
| "Obesity is often associated with chronic inflammatory state which contributes to the development of insulin resistance (IR) and type 2 diabetes mellitus (T2DM)." | 1.39 | Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats. ( El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A, 2013) |
| " The purpose of this study was to determine the relative effects of these three modes of pharmacological RAS inhibition in reducing atherosclerosis by determining the dose-response relationships." | 1.38 | Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis. ( Balakrishnan, A; Cassis, LA; Charnigo, R; Daugherty, A; Howatt, DA; Liau, G; Lu, H; Wu, C, 2012) |
| "Losartan was used as a probe drug to determine CYP2C9 metabolic activity." | 1.37 | Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients. ( Babaoglu, MO; Bozkurt, A; Kilicarslan, A; Sain-Guven, G; Yardimci, Y; Yasar, U, 2011) |
| "Hypercholesterolemia was associated with increased CD34(+) cell AT(1) receptor expression and an exaggerated in vitro myeloproliferative response to angiotensin II stimulation that positively correlated to plasma LDL concentrations." | 1.35 | Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys. ( Ferrario, CM; Strawn, WB, 2008) |
| " In summary, according to this retrospective pilot study, DALI-LDL-apheresis was shown for the first time to be safe and effective in patients on ARA medication." | 1.32 | Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 antagonist losartan. ( Bosch, T; Wendler, T, 2004) |
| "We have established a reproducible stenosis model in hypercholesterolemic hamsters, and the process of arterial stenosis by thrombus or neointima was studied and compared with that in normal hamsters." | 1.31 | Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters. ( Abe, A; Kozawa, O; Matsuno, H; Niwa, M; Takiguchi, Y; Uematsu, T, 2001) |
| "Losartan-treated rabbits revealed a reduction in immunohistochemical expression of MMP-1, whereas TIMP-2 expression became localized to the intima." | 1.31 | Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits. ( Chen, H; Li, D; Mehta, JL, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 21 (61.76) | 29.6817 |
| 2010's | 10 (29.41) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Muñoz, D | 1 |
| Uzoije, P | 1 |
| Reynolds, C | 1 |
| Miller, R | 1 |
| Walkley, D | 1 |
| Pappalardo, S | 1 |
| Tousey, P | 1 |
| Munro, H | 1 |
| Gonzales, H | 1 |
| Song, W | 1 |
| White, C | 1 |
| Blot, WJ | 1 |
| Wang, TJ | 1 |
| AlSaad, AMS | 1 |
| Alasmari, F | 1 |
| Abuohashish, HM | 1 |
| Mohany, M | 1 |
| Ahmed, MM | 1 |
| Al-Rejaie, SS | 1 |
| Abdel-Zaher, AO | 2 |
| Farghaly, HSM | 1 |
| El-Refaiy, AEM | 1 |
| Abd-Eldayem, AM | 1 |
| Lee, HY | 1 |
| Kim, SY | 1 |
| Choi, KJ | 1 |
| Yoo, BS | 1 |
| Cha, DH | 1 |
| Jung, HO | 1 |
| Ryu, DR | 1 |
| Choi, JH | 1 |
| Lee, KJ | 1 |
| Park, TH | 1 |
| Oh, JH | 1 |
| Kim, SM | 1 |
| Choi, JY | 1 |
| Kim, KH | 1 |
| Shim, J | 1 |
| Kim, WS | 1 |
| Choi, SW | 1 |
| Park, DG | 1 |
| Song, PS | 1 |
| Hong, TJ | 1 |
| Rhee, MY | 1 |
| Rha, SW | 1 |
| Park, SW | 1 |
| Elkoussi, AE | 1 |
| Abudahab, LH | 1 |
| Elbakry, MH | 1 |
| Elsayed, EA | 1 |
| Maczewski, M | 1 |
| Maczewska, J | 1 |
| Duda, M | 1 |
| Krikken, JA | 1 |
| Waanders, F | 1 |
| Dallinga-Thie, GM | 1 |
| Dikkeschei, LD | 1 |
| Vogt, L | 1 |
| Navis, GJ | 1 |
| Dullaart, RP | 1 |
| Woo, KT | 1 |
| Wong, KS | 1 |
| Chan, CM | 1 |
| Kosmadakis, G | 1 |
| Filiopoulos, V | 1 |
| Georgoulias, C | 1 |
| Tentolouris, N | 1 |
| Michail, S | 1 |
| Yasar, U | 1 |
| Sain-Guven, G | 1 |
| Yardimci, Y | 1 |
| Kilicarslan, A | 1 |
| Babaoglu, MO | 1 |
| Bozkurt, A | 1 |
| Grosch, S | 1 |
| Van Overmeire, L | 1 |
| Krzesinski, JM | 1 |
| Bovy, C | 1 |
| Lu, H | 1 |
| Balakrishnan, A | 1 |
| Howatt, DA | 1 |
| Wu, C | 1 |
| Charnigo, R | 1 |
| Liau, G | 1 |
| Cassis, LA | 1 |
| Daugherty, A | 1 |
| Mourad, AA | 1 |
| Heeba, GH | 1 |
| Taye, A | 1 |
| El-Moselhy, MA | 1 |
| Wald, DS | 1 |
| Morris, JK | 1 |
| Wald, NJ | 1 |
| Andréjak, M | 1 |
| Gayet, JL | 1 |
| Ambrosi, P | 1 |
| Bosch, T | 1 |
| Wendler, T | 1 |
| Graninger, M | 1 |
| Reiter, R | 1 |
| Drucker, C | 1 |
| Minar, E | 1 |
| Jilma, B | 1 |
| Koh, KK | 2 |
| Quon, MJ | 2 |
| Han, SH | 2 |
| Chung, WJ | 1 |
| Ahn, JY | 1 |
| Seo, YH | 1 |
| Kang, MH | 1 |
| Ahn, TH | 1 |
| Choi, IS | 1 |
| Shin, EK | 2 |
| Kizer, JR | 1 |
| Dahlöf, B | 1 |
| Kjeldsen, SE | 1 |
| Julius, S | 1 |
| Beevers, G | 1 |
| de Faire, U | 1 |
| Fyhrquist, F | 1 |
| Ibsen, H | 1 |
| Kristianson, K | 1 |
| Lederballe-Pedersen, O | 1 |
| Lindholm, LH | 1 |
| Nieminen, MS | 1 |
| Omvik, P | 1 |
| Oparil, S | 1 |
| Wedel, H | 1 |
| Wachtell, K | 1 |
| Edelman, JM | 1 |
| Snapinn, SM | 1 |
| Harris, KE | 1 |
| Devereux, RB | 1 |
| Petnehazy, T | 1 |
| Stokes, KY | 1 |
| Russell, JM | 1 |
| Granger, DN | 1 |
| Lee, Y | 1 |
| Xu, G | 1 |
| Li, XS | 1 |
| Huang, WQ | 1 |
| Huang, H | 1 |
| Usher-Smith, JA | 1 |
| Ramsbottom, T | 2 |
| Pearmain, H | 2 |
| Kirby, M | 2 |
| Strawn, WB | 2 |
| Ferrario, CM | 2 |
| Gerster, JC | 1 |
| Usher-Smith, J | 1 |
| Makaritsis, KP | 1 |
| Gavras, H | 1 |
| Du, Y | 1 |
| Chobanian, AV | 1 |
| Brecher, P | 1 |
| Chappell, MC | 1 |
| Dean, RH | 1 |
| Kivlighn, S | 1 |
| Hayek, T | 1 |
| Aviram, M | 1 |
| Heinrich, R | 1 |
| Sakhnini, E | 1 |
| Keidar, S | 1 |
| Chen, H | 2 |
| Li, D | 2 |
| Sawamura, T | 1 |
| Inoue, K | 1 |
| Mehta, JL | 2 |
| Matsuno, H | 1 |
| Kozawa, O | 1 |
| Niwa, M | 1 |
| Abe, A | 1 |
| Takiguchi, Y | 1 |
| Uematsu, T | 1 |
| Sanz, M | 1 |
| Ganado, P | 1 |
| Tejerina, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Polypill Strategy for Evidence-Based Management of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention in an Underserved Patient Population[NCT05514938] | Phase 2 | 60 participants (Anticipated) | Interventional | 2022-11-30 | Recruiting | ||
| Developing a Heart Failure Polypill to Improve Outcomes at a Safety Net Hospital: A Pilot Crossover Randomized Controlled Trial[NCT06029712] | Phase 2 | 40 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| The SCCS Polypill Pilot Trial[NCT02278471] | Phase 2 | 303 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Efficacy and Safety of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia: A Randomized, Double-blind, Multicenter, Phase 3 Study[NCT02899455] | Phase 3 | 146 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Fixed Combination for Lipid and Blood Pressure Control. Randomized Cross-over Study[NCT03047538] | Phase 4 | 0 participants (Actual) | Interventional | 2017-09-01 | Withdrawn (stopped due to Insufficient funds) | ||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 109 |
| Polypill | 98 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mg/dL (Mean) |
|---|---|
| Usual Care | 108 |
| Polypill | 90 |
polypill-percentage of pills taken, evaluated via pill counts (NCT02278471)
Timeframe: 2 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 98 |
polypill arm-evaluation via pill counts. (NCT02278471)
Timeframe: 12 months
| Intervention | percentage of pills taken (Median) |
|---|---|
| Polypill | 86 |
polypill versus usual care (NCT02278471)
Timeframe: 12 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 138 |
| Polypill | 131 |
polypill versus usual care (NCT02278471)
Timeframe: 2 months
| Intervention | mm Hg (Mean) |
|---|---|
| Usual Care | 133 |
| Polypill | 128 |
3 reviews available for losartan and Hypercholesterolemia
| Article | Year |
|---|---|
Clinical trials of the past decade in the management of chronic kidney disease.
Topics: Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyper | 2009 |
[The best of clinical pharmacology in 2002].
Topics: Anticholesteremic Agents; Antihypertensive Agents; Azetidines; Cardiovascular Diseases; Ezetimibe; H | 2003 |
[Involvement of the foot in metabolic diseases].
Topics: Achilles Tendon; Acute Disease; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Apatites; Chon | 2007 |
10 trials available for losartan and Hypercholesterolemia
| Article | Year |
|---|---|
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Healt | 2019 |
A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Comorbidity; Do | 2017 |
Effect of simvastatin on the antihypertensive activity of losartan in hypertensive hypercholesterolemic animals and patients: role of nitric oxide, oxidative stress, and high-sensitivity C-reactive protein.
Topics: Adult; Aged; Animals; Anticholesteremic Agents; Antihypertensive Agents; Aorta; Blood Pressure; C-Re | 2014 |
Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin.
Topics: Adiponectin; Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Cholesterol Ester Transfer Protei | 2009 |
Comparison of the influence of angiotensin-converting enzyme inhibitor lisinopril and angiotensin II receptor antagonist losartan in patients with idiopathic membranous nephropathy and nephrotic syndrome.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inh | 2010 |
Randomized Polypill crossover trial in people aged 50 and over.
Topics: Aged; Amlodipine; Anticholesteremic Agents; Antihypertensive Agents; Blood Pressure; Cardiovascular | 2012 |
Angiotensin receptor blockade decreases markers of vascular inflammation.
Topics: Angiotensin Receptor Antagonists; Blood Pressure; Cholesterol; Double-Blind Method; E-Selectin; Enal | 2004 |
Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients.
Topics: Adiponectin; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Blood Pressure; C-Reactive Protein | 2004 |
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.
Topics: Aged; Aged, 80 and over; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atenolol; | 2005 |
The effects of simvastatin, losartan, and combined therapy on soluble CD40 ligand in hypercholesterolemic, hypertensive patients.
Topics: Antihypertensive Agents; Blood Pressure; C-Reactive Protein; CD40 Ligand; Cross-Over Studies; Drug T | 2007 |
21 other studies available for losartan and Hypercholesterolemia
| Article | Year |
|---|---|
Renin angiotensin system blockage by losartan neutralize hypercholesterolemia-induced inflammatory and oxidative injuries.
Topics: Animals; Antihypertensive Agents; Cholesterol, Dietary; Hypercholesterolemia; Inflammation; Losartan | 2020 |
Protective effect of the standardized extract of ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms.
Topics: Animals; Blood Pressure; Creatinine; Diastole; Ginkgo biloba; Glutathione; Hypercholesterolemia; Hyp | 2017 |
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Thera | 2008 |
Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C9; Female; Heptanoic Acids; Human | 2011 |
[Fibrillary nonamyloid glomerulonephritis: a rare etiology of nephrotic syndrome].
Topics: Coloring Agents; Complement C3; Congo Red; Diagnosis, Differential; Edema; Female; Fluorobenzenes; G | 2011 |
Comparative effects of different modes of renin angiotensin system inhibition on hypercholesterolaemia-induced atherosclerosis.
Topics: Amides; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhib | 2012 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, | 2013 |
Efficacy and safety of DALI-LDL-apheresis in two patients treated with the angiotensin II-receptor 1 antagonist losartan.
Topics: Absorption; Adult; Antihypertensive Agents; Blood Chemical Analysis; Blood Component Removal; Contra | 2004 |
Angiotensin II type-1 receptor antagonism attenuates the inflammatory and thrombogenic responses to hypercholesterolemia in venules.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Platelets; Cell Movement; Endothelium, Vascu | 2005 |
[Effect of probucol and losartan on growth factors after balloon angioplasty in rabbits].
Topics: Angioplasty, Balloon; Animals; Anticholesteremic Agents; Coronary Restenosis; Drug Therapy, Combinat | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Ben | 2007 |
Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys.
Topics: Angiotensin II; Animals; Antigens, CD34; Bone Marrow Cells; CD11b Antigen; Cholesterol; Cholesterol, | 2008 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidaz | 2008 |
I'm a 57-year-old man with high blood pressure and high cholesterol. I had a hard time regulating my pressure until I went on Vasotec, which was great. But I developed a cough, so my doctor switched me to Cozaar. My cough stopped and my pressure seems oka
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Enalapril; Humans; Hypercholester | 1998 |
Alpha1-adrenergic plus angiotensin receptor blockade reduces atherosclerosis in apolipoprotein E-deficient mice.
Topics: Adrenergic alpha-Antagonists; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Ap | 1998 |
Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia.
Topics: Angiotensin Receptor Antagonists; Animals; Arteriosclerosis; Biomarkers; Diet; Hypercholesterolemia; | 2000 |
Losartan inhibits cellular uptake of oxidized LDL by monocyte-macrophages from hypercholesterolemic patients.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Arteriosclerosis; Biological Transport, Active; CD | 2000 |
Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan.
Topics: Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Aorta; Arteriosclerosis; Body We | 2000 |
Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters.
Topics: Animals; Becaplermin; Blood Flow Velocity; Carotid Arteries; Carotid Artery Thrombosis; Cells, Cultu | 2001 |
Modulation of matrix metalloproteinase-1, its tissue inhibitor, and nuclear factor-kappa B by losartan in hypercholesterolemic rabbits.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Abdominal; Arteriosclerosis; Blott | 2002 |
Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterol-fed rabbits.
Topics: Acetylcholine; Angiotensin Receptor Antagonists; Animals; Aorta, Thoracic; Biphenyl Compounds; Chole | 2002 |